Georgia 2025-2026 Regular Session

Georgia Senate Bill SB220

Introduced
2/19/25  
Refer
2/20/25  
Report Pass
2/27/25  
Engrossed
3/6/25  

Caption

"Putting Georgia's Patients First Act"; enact

Impact

The passage of SB 220 would significantly impact existing laws related to cannabis use and access in Georgia. Key changes include the repeal of previous prohibitions on certain methods of ingestion, increased clarity around registration processes for patients, and an emphasis on compliance by production and distribution entities. The bill aims to ensure that patients have lawful access to medical cannabis while maintaining stringent oversight and compliance standards, which could lead to more patients utilizing cannabis for therapeutic purposes. The amendments also seek to provide state-level protections for licensed individuals against criminal liability when operating within the framework of the new regulations.

Summary

Senate Bill 220, also known as the 'Putting Georgia's Patients First Act', proposes comprehensive changes to the regulation of medical cannabis in Georgia. The bill redefines 'low THC oil' to be referred to as 'medical cannabis' and amends various provisions in the Official Code of Georgia Annotated. It outlines the establishment of a medical cannabis patient registry, updates definitions and regulations surrounding the manufacture, distribution, and use of medical cannabis, and clarifies criminal penalties associated with violations of these regulations. This bill aims to enhance accessibility and provide better oversight of medical cannabis in the state, showcasing a shift towards a more regulated medical cannabis framework.

Sentiment

The sentiment around SB 220 appears to be largely positive among supporters who view it as a necessary step for patients in need of medical cannabis for chronic or severe conditions. Advocates emphasize the importance of a regulated system to ensure safety and efficacy in the delivery of medical cannabis. However, some concerns may arise regarding potential oversights in the legislation, such as the balance between regulatory compliance and patient access. Opponents of regulatory frameworks have historically argued that excessive regulation can lead to barriers for patients, hence the discussions around SB 220 are likely to reflect both hopeful optimism and caution regarding the practical ramifications of such laws.

Contention

Notable points of contention stem from proposed changes to the responsibilities and powers of the Georgia Access to Medical Cannabis Commission, particularly around its authority to regulate the distribution network for medical cannabis. Some stakeholders may question whether the bill adequately addresses patient rights or if it imposes burdensome requirements on healthcare providers and dispensaries. The inclusion of penalties for violations and the balance between public health oversight versus accessibility for patients are also likely areas of debate. The evolution of criminal penalties related to cannabis possession and the implications for registered patients may spark significant discussions and potential adjustments during legislative proceedings.

Companion Bills

No companion bills found.

Similar Bills

NJ A5068

Permits Department of Agriculture to regulate sale and distribution of hemp-derived consumable products under certain circumstances.

HI SB1655

Relating To Manufactured Hemp Products.

GA HB265

Georgia Hemp Farming Act; provide limits on the total concentration of THC and other intoxicating cannabinoids in consumable hemp products

NJ S3235

Regulates production and sale of certain intoxicating hemp products.

NJ A4461

Regulates production and sale of certain intoxicating hemp products.

GA SB33

"Georgia Hemp Farming Act"; total THC concentration of consumable hemp products; provide limits

GA HB227

Putting Georgia's Patients First Act; enact

HI HB217

Relating To Marijuana.